153 related articles for article (PubMed ID: 35080260)
1. BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies.
Zengarini C; Mussi M; Veronesi G; Alessandrini A; Lambertini M; Dika E
Clin Exp Dermatol; 2022 Jun; 47(6):1131-1136. PubMed ID: 35080260
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and genetic characterization of invasive melanoma with BRAF V600K mutation: A study of 16 cases.
Goto K; Yoshikawa S; Takai T; Tachibana K; Honma K; Isei T; Kukita Y; Oishi T
J Cutan Pathol; 2023 Aug; 50(8):739-747. PubMed ID: 37226844
[TBL] [Abstract][Full Text] [Related]
3. Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K
Pires da Silva I; Wang KYX; Wilmott JS; Holst J; Carlino MS; Park JJ; Quek C; Wongchenko M; Yan Y; Mann G; Johnson DB; McQuade JL; Rai R; Kefford RF; Rizos H; Scolyer RA; Yang JYH; Long GV; Menzies AM
Clin Cancer Res; 2019 Feb; 25(4):1272-1279. PubMed ID: 30630828
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
5. Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.
Li Y; Umbach DM; Li L
Melanoma Res; 2017 Dec; 27(6):527-535. PubMed ID: 28858076
[TBL] [Abstract][Full Text] [Related]
6. BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
Ponti G; Tomasi A; Maiorana A; Ruini C; Maccaferri M; Cesinaro AM; Depenni R; Manni P; Gelsomino F; Giusti F; Garagnani L; Pellacani G
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):30-4. PubMed ID: 26633701
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.
Bucheit AD; Syklawer E; Jakob JA; Bassett RL; Curry JL; Gershenwald JE; Kim KB; Hwu P; Lazar AJ; Davies MA
Cancer; 2013 Nov; 119(21):3821-9. PubMed ID: 23922205
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
McArthur GA; Chapman PB; Robert C; Larkin J; Haanen JB; Dummer R; Ribas A; Hogg D; Hamid O; Ascierto PA; Garbe C; Testori A; Maio M; Lorigan P; Lebbé C; Jouary T; Schadendorf D; O'Day SJ; Kirkwood JM; Eggermont AM; Dréno B; Sosman JA; Flaherty KT; Yin M; Caro I; Cheng S; Trunzer K; Hauschild A
Lancet Oncol; 2014 Mar; 15(3):323-32. PubMed ID: 24508103
[TBL] [Abstract][Full Text] [Related]
9. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
Menzies AM; Haydu LE; Visintin L; Carlino MS; Howle JR; Thompson JF; Kefford RF; Scolyer RA; Long GV
Clin Cancer Res; 2012 Jun; 18(12):3242-9. PubMed ID: 22535154
[TBL] [Abstract][Full Text] [Related]
10. A HRM assay for identification of low level BRAF V600E and V600K mutations using the CADMA principle in FFPE specimens.
Huebner C; Weber R; Lloydd R
Pathology; 2017 Dec; 49(7):776-783. PubMed ID: 29100713
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
Hallmeyer S; Gonzalez R; Lawson DH; Cranmer LD; Linette GP; Puzanov I; Taback B; Cowey CL; Ribas A; Daniels GA; Moore T; Gibney GT; Tawbi H; Whitman E; Lee G; Mun Y; Liu S; Hamid O
Melanoma Res; 2017 Dec; 27(6):585-590. PubMed ID: 29076950
[TBL] [Abstract][Full Text] [Related]
13. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
[TBL] [Abstract][Full Text] [Related]
14. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
Rubinstein JC; Sznol M; Pavlick AC; Ariyan S; Cheng E; Bacchiocchi A; Kluger HM; Narayan D; Halaban R
J Transl Med; 2010 Jul; 8():67. PubMed ID: 20630094
[TBL] [Abstract][Full Text] [Related]
15. Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.
Dudley JC; Gurda GT; Tseng LH; Anderson DA; Chen G; Taube JM; Gocke CD; Eshleman JR; Lin MT
Mol Diagn Ther; 2014 Aug; 18(4):409-18. PubMed ID: 24604154
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E Mutation in Malignant Melanoma-A Romanian Research Experience.
Avădănei ER; Căruntu ID; Nucă I; Balan R; Lozneanu L; Giusca SE; Amalinei C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541077
[No Abstract] [Full Text] [Related]
17. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
18. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
19. Histologic and Phenotypic Factors and MC1R Status Associated with BRAF(V600E), BRAF(V600K), and NRAS Mutations in a Community-Based Sample of 414 Cutaneous Melanomas.
Hacker E; Olsen CM; Kvaskoff M; Pandeya N; Yeo A; Green AC; Williamson RM; Triscott J; Wood D; Mortimore R; Hayward NK; Whiteman DC
J Invest Dermatol; 2016 Apr; 136(4):829-837. PubMed ID: 26807515
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600 Mutation Profile of Metastatic Melanoma in the Thrace Region of Turkey.
Can N; Taştekin E; Deniz Yalta T; Süt N; Korkmaz S; Usta U; Öz Puyan F; Genç E; Cezik M; Binboğa Tutuğ B; Köstek O; Tozkir H
Turk Patoloji Derg; 2018 Feb; ():. PubMed ID: 29419849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
